The Effect of Carriage of <i>CYP3A5*3</i> and <i>CYP3A4*22</i> Polymorphic Variants on the Safety of Remdesivir Therapy in Patients with COVID-19
The aim of the study was to assess the association of polymorphic variants CYP3A5*3 6986 A>G rs776746 and CYP3A4*22 rs35599367 C>T with the safety parameters of remdesivir therapy in patients with COVID-19.Material and methods. The study included 156 patients admitted to the City Clini...
Saved in:
Main Authors: | I. I. TEMIRBULATOV, A. V. KRYUKOV, K. B. MIRZAEV, N. P. DENISENKO, S. P. ABDULLAEV, A. S. ZHIRYAKOVA, Y. V. SHEVCHUK, V. I. VECHORKO, O. V. AVERKOV, D. A. SYCHEV |
---|---|
Format: | Article |
Language: | Russian |
Published: |
LLC "Publishing House OKI"
2022-11-01
|
Series: | Антибиотики и Химиотерапия |
Subjects: | |
Online Access: | https://www.antibiotics-chemotherapy.ru/jour/article/view/947 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Model for predicting risk of developing drug-induced liver injury during remdesivir therapy: observational prospective open case-control study
by: Yu. V. Shevchuk, et al.
Published: (2023-11-01) -
Predicting the risk of developing drug-induced liver injury during remdesivir therapy in COVID-19 patients using machine learning
by: Yu. V. Shevchuk, et al.
Published: (2024-12-01) -
Association of CYP3A4*1B, CYP3A4*22 and CYP3A5*3 polymorphisms carriage with efficacy and safety of tamsulosin in patients with benign prostatic hyperplasia
by: Sh. P. Abdullaev, et al.
Published: (2024-05-01) -
The rs11385942 and rs657152 variants are not associated with COVID-19 severity and outcomes in patients treated with favipiravir and remdesivir
by: Sh. P. Abdullaev, et al.
Published: (2024-01-01) -
Effect of <i>CYP1A2</i>, <i>CYP2D6</i>, and <i>CYP3A4</i> Variation on Antipsychotic Treatment Outcomes
by: Lauren Varney, et al.
Published: (2025-06-01)